Research Update

Brown, C.J.; Kent, Heather
August 1999
CMAJ: Canadian Medical Association Journal;8/24/99, Vol. 161 Issue 4, p364
Academic Journal
Updates research and medical news for August 24, 1999. Details of the Randomized Aldactone Evaluation Study, which showed that aldosterone antagonist spironolactone cuts the risk of death and the rate of hospitalization in patients with severe heart failure; Research by Dr. Marianne Sadar explaining why some prostate cancer tumors grow even without androgen; The May decision by the United Kingdom's High Court dealing with patient information that has been rendered anonymous.


Related Articles

  • Lack of adherence in heart failure therapy.  // Hospital Home Health;Apr2010, Vol. 27 Issue 4, p45 

    The article reports on a research finding which reveals that majority of heart failure patients who are eligible for aldosterone antagonist therapy are not receiving the said treatment.

  • Lack of adherence in heart failure therapy.  // Hospital Home Health;May2010, Vol. 27 Issue 5, p52 

    The article discusses the study which reveals that physicians and hospitals failed to adhere the adoption of new treatment recommendations aldosterone antagonist therapy to help improve the patient outcomes in hospitalized heart failure patients in the U.S.

  • 335 Antialdosterone therapy improves lung diffusion in heart failure. Andreini, D.; Magini, A.; Apostolo, A.; Palermo, P.; Cattadori, G.; Contini, M.; Bussotti, M.; Agostoni, P.G. // European Journal of Heart Failure. Supplements;Jun2004, Vol. 3 Issue 1, p84 

    An abstract of the study "Antialdosterone therapy improves lung diffusion in heart failure," by D. Andreini and colleagues is presented.

  • 534 Aldosterone antagonists in chronic heart failure outpatients. Borelli, G.; Zingaro, S.; Coceani, M.; Guideri, S.; Rondinini, L.; Mariotti, R. // European Journal of Heart Failure. Supplements;Jun2006, Vol. 5 Issue 1, p116 

    An abstract of the study "Aldosterone Antagonists in Chronic Heart Failure Outpatients," by G. Borelli and colleagues is presented.

  • Eplerenone appears cost effective in EPHESUS study.  // PharmacoEconomics & Outcomes News;2/6/2010, Issue 596, p9 

    The article focuses on the study "Cost-effectiveness of Eplerenon in Patients with Heart Failure After Acute Myocardial Infarction Who Were Taking Both ACE Inhibitors and Beta-blockers: Subanalysis of the EPHESUS," by Z. Zhang et al., published in an issue of the "American Journal of...

  • New data from studies bolsters case for using aldosterone antagonists in heart failure.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p836 

    The article reports that medical expert Bertram Pitt will review the data from three prominent studies on aldosterone antagonists for heart failure therapy in a presentation at the American Physiological Society conference.

  • Aldosterone antagonists in heart failure with reduced ejection fraction. O'Donovan, Kate // Nurse Prescribing;2015, Vol. 13 Issue 5, p242 

    Heart failure with reduced ejection fraction is associated with increased mortality, limited functional capacity and poor quality of life. The renin--angiotensin--aldosterone system (RAAS) is an essential compensatory mechanism that attempts to maintain organ perfusion. The secretion of...

  • Benefits and Consequences of Aldosterone Antagonists for HF. Kuritzky, Louis // Internal Medicine Alert;1/15/2013, Vol. 35 Issue 1, p7 

    The article discusses a study which analyses the benefits and consequences of aldosterone antagonist therapy for heart failure patients.

  • Benefits and Consequences of Aldosterone Antagonists for HF. Kuritzky, Louis // OB/GYN Clinical Alert;Feb2013 Clinical Briefs in Primary Care, p3 

    The article focuses on the results of clinical trials regarding the benefits and consequences of aldosterone antagonist therapy in chronic heart failure (CHF) patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics